zurück

Tisagenlecleucel (new indication: follicular lymphoma (FL), pretreated patients)


Subject:

  • Active Substance: Tisagenlecleucel
  • Name: Kymriah®
  • Therapeutic area: Follicular lymphoma (FL)
  • Pharmaceutical company: Novartis Pharma GmbH


Time table:

  • Start: 01.06.2022
  • Final decision by G-BA: 01.12.2022


Final decision:

  • Hint for a non-quantifiable additional benefit